NCT07052578 Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
| NCT ID | NCT07052578 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 230 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 230 participants in total. It began in 2025-06-30 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
Eligibility Criteria
Inclusion Criteria: 1. Male patients aged ≥ 18 years old; 2. Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing; 3. Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages); 4. High-aggressive disease (Gleason 8-10); 5. High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis); 6. Availability of source medical documentation; 7. Known HRRm status based on routine tumour sample analysis. Exclusion Criteria: 1. Participation in any interventional trial since the mPC diagnosis. 2. Progression to mCRPC.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07052578 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07052578 currently recruiting?
Yes, NCT07052578 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07052578 trial being conducted?
This trial is being conducted at Arkhangelsk, Russia, Barnaul, Russia, Chelyabinsk, Russia, Irkutsk, Russia and 11 additional locations.
Who is sponsoring the NCT07052578 clinical trial?
NCT07052578 is sponsored by AstraZeneca. The trial plans to enroll 230 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.